.jpg)
BIOMARKERS FOR NON-INVASIVE DETECTION AND CLASSIFICATION OF PROSTATE CANCER
Three new biomarkers for the prognosis, stratification and prostate cancer monitoring have been identified: PCA3, MRC2, and S100A4. These biomarkers could be detected by non-invasive methods, such as liquid biopsy, and be used as a component for kits and devices with the same purpose.
- Tissue and cancer specificity: PCA3 is expressed only in prostatic tissue, overcoming the main disadvantage of PSA. - High accuracy and early detection. PCA3 is overexpressed in more than 95% primary prostate cancers. - Custom medicine. Expression levels of PCA3, MRC2 and S100A4 will allow to define the most adequate treatment. - Non-invasive and real-time analysis. Biomarkers can be detected with non-invasive methods, such as liquid biopsy, which allows multiple analysis along tumor process. - Simple method. A kit or device would ease data obtaining.